Journal article
Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial
- Abstract:
-
Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide–1 receptor agonist, which canimprove glycemic control, body weight, blood pressure, and lipid levels in patients with type 2 diabetes mellitus (T2DM). TheEXenatide Study of Cardiovascular Event Lowering (EXSCEL) will compare the impact of adding exenatide once-weekly to usualcare with usual care alone on major cardiovascular outcomes.EXSCEL is an academically led, phase III/IV, double-blind, pragmat...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 264.8KB)
-
- Publisher copy:
- 10.1016/j.ahj.2015.12.009
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- American Heart Journal Journal website
- Volume:
- 174
- Pages:
- 103-110
- Publication date:
- 2015-12-21
- Acceptance date:
- 2015-12-14
- DOI:
- EISSN:
-
1097-6744
- ISSN:
-
0002-8703
- Pmid:
-
26995376
- Source identifiers:
-
611243
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:611243
- UUID:
-
uuid:38012ace-45f6-47fd-b797-03a947e229d3
- Local pid:
- pubs:611243
- Deposit date:
- 2017-05-30
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2015
- Notes:
- © 2015 Elsevier Inc. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.ahj.2015.12.009
If you are the owner of this record, you can report an update to it here: Report update to this record